Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 gp130 at the nexus of inflammation, autoimmunity, and cancer.

Literature DB >> 20610800

gp130 at the nexus of inflammation, autoimmunity, and cancer.

Abstract

Glycoprotein 130 (gp130) is a shared receptor utilized by several related cytokines, including IL-6, IL-11, IL-27, Leukemia Inhibitory Factor (LIF), Oncostatin M (OSM), Ciliary Neurotrophic Factor (CNTF), Cardiotrophin 1 (CT-1) and Cardiotrophin-like Cytokine (CLC). Gp130 plays critical roles during development and gp130-deficient mice are embryonically lethal. However, the best characterized facet of this receptor and its associated cytokines is the ability to promote or suppress inflammation. The aim of this review is to discuss the role of gp130 in promoting or preventing the development of autoimmunity and cancer, two processes that are associated with aberrant inflammatory responses.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2010 PMID： 20610800 PMCID： PMC2996896 DOI： 10.1189/jlb.0410217

Source DB: PubMed Journal: J Leukoc Biol ISSN： 0741-5400 Impact factor: 4.962

195 in total

1. gp130, the cytokine common signal-transducer of interleukin-6 cytokine family, is downregulated in T cells in vivo by interleukin-6.

Authors: X J Wang; T Taga; K Yoshida; M Saito; T Kishimoto; H Kikutani
Journal: Blood Date: 1998-05-01 Impact factor: 22.113

2. Oncostatin M stimulates excessive extracellular matrix accumulation in a transgenic mouse model of connective tissue disease.

Authors: B Bamber; R A Reife; H S Haugen; C H Clegg
Journal: J Mol Med (Berl) Date: 1998-01 Impact factor: 4.599

3. Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies.

Authors: J Usón; A Balsa; D Pascual-Salcedo; J A Cabezas; J M Gonzalez-Tarrio; E Martín-Mola; G Fontan
Journal: J Rheumatol Date: 1997-11 Impact factor: 4.666

4. Oncostatin M stimulates monocyte chemoattractant protein-1- and interleukin-1-induced matrix metalloproteinase-1 production by human synovial fibroblasts in vitro.

Authors: C Langdon; J Leith; F Smith; C D Richards
Journal: Arthritis Rheum Date: 1997-12

5. Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid.

Authors: A Desgeorges; C Gabay; P Silacci; D Novick; P Roux-Lombard; G Grau; J M Dayer; T Vischer; P A Guerne
Journal: J Rheumatol Date: 1997-08 Impact factor: 4.666

6. Oncostatin M induces the differentiation of breast cancer cells.

Authors: A M Douglas; S L Grant; G A Goss; D R Clouston; R L Sutherland; C G Begley
Journal: Int J Cancer Date: 1998-01-05 Impact factor: 7.396

7. Central role of IL-6 receptor signal-transducing chain gp130 in activation of L-selectin adhesion by fever-range thermal stress.

Authors: Qing Chen; Wan Chao Wang; Robert Bruce; Hong Li; David M Schleider; Michael J Mulbury; Mark D Bain; Paul K Wallace; Heinz Baumann; Sharon S Evans
Journal: Immunity Date: 2004-01 Impact factor: 31.745

8. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease.

Authors: Hiroaki Ito; Masakazu Takazoe; Yoshihiro Fukuda; Toshifumi Hibi; Kazuo Kusugami; Akira Andoh; Takayuki Matsumoto; Takehira Yamamura; Junichi Azuma; Norihiro Nishimoto; Kazuyuki Yoshizaki; Takashi Shimoyama; Tadamitsu Kishimoto
Journal: Gastroenterology Date: 2004-04 Impact factor: 22.682

9. Interleukin 6 is required for the development of collagen-induced arthritis.

Authors: T Alonzi; E Fattori; D Lazzaro; P Costa; L Probert; G Kollias; F De Benedetti; V Poli; G Ciliberto
Journal: J Exp Med Date: 1998-02-16 Impact factor: 14.307

10. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis.

Authors: Vissia Viglietta; Clare Baecher-Allan; Howard L Weiner; David A Hafler
Journal: J Exp Med Date: 2004-04-05 Impact factor: 14.307

103 in total

1. IL-10-induced gp130 expression in mouse mast cells permits IL-6 trans-signaling.

Authors: Daniel Traum; Patricia Timothee; Jonathan Silver; Stefan Rose-John; Matthias Ernst; David F LaRosa
Journal: J Leukoc Biol Date: 2011-12-02 Impact factor: 4.962

2. The composition and signaling of the IL-35 receptor are unconventional.

Authors: Lauren W Collison; Greg M Delgoffe; Clifford S Guy; Kate M Vignali; Vandana Chaturvedi; DeLisa Fairweather; Abhay R Satoskar; K Christopher Garcia; Christopher A Hunter; Charles G Drake; Peter J Murray; Dario A A Vignali
Journal: Nat Immunol Date: 2012-02-05 Impact factor: 25.606

3. Cell-intrinsic IL-27 and gp130 cytokine receptor signaling regulates virus-specific CD4⁺ T cell responses and viral control during chronic infection.

Authors: James A Harker; Aleksandr Dolgoter; Elina I Zuniga
Journal: Immunity Date: 2013-08-29 Impact factor: 31.745

Review 4. Eliminative signaling by Janus kinases: role in the downregulation of associated receptors.

Authors: Christopher J Carbone; Serge Y Fuchs
Journal: J Cell Biochem Date: 2014-01 Impact factor: 4.429

Review 5. Omega-3 fatty acids, lipid rafts, and T cell signaling.

Authors: Tim Y Hou; David N McMurray; Robert S Chapkin
Journal: Eur J Pharmacol Date: 2015-05-20 Impact factor: 4.432

6. Pathogenic Transdifferentiation of Th17 Cells Contribute to Perpetuation of Rheumatoid Arthritis during Anti-TNF Treatment.

Authors: Karin M E Andersson; Nicola Filluelo Cavallini; Dan Hu; Mikael Brisslert; Ron Cialic; Hadi Valadi; Malin C Erlandsson; Sofia Silfverswärd; Rille Pullerits; Vijay K Kuchroo; Howard L Weiner; Maria I Bokarewa
Journal: Mol Med Date: 2015-06-04 Impact factor: 6.354